FDA’s Proposed Guidance for Laboratory Developed Tests: How Should Regulators Balance the Risks and Promise of Innovation in Clinical Genetics?

Lignende værker

• The FDA’s New Guidance for Off-Label Promotion Is Only a Start
  af: Field, Robert I.
  Udgivet: (2008)
• FDA guidance for next generation sequencing-based testing: balancing regulation and innovation in precision medicine
  af: Luh, Frank, et al.
  Udgivet: (2018)
• FDA’s commitment to transparency
  af: Guharoy, Roy, et al.
  Udgivet: (2021)
• Pharmacists Welcome FDA’s Opioids REMS: How Directly Will They Be Affected?
  af: Barlas, Stephen
  Udgivet: (2012)
• OpenFDA: an innovative platform providing access to a wealth of FDA’s publicly available data
  af: Kass-Hout, Taha A, et al.
  Udgivet: (2016)